BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25490988)

  • 1. Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models.
    Taylor JM; Conlon AS; Elliott MR
    Clin Trials; 2015 Aug; 12(4):317-22. PubMed ID: 25490988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogacy assessment using principal stratification and a Gaussian copula model.
    Conlon A; Taylor J; Elliott MR
    Stat Methods Med Res; 2017 Feb; 26(1):88-107. PubMed ID: 24947559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.
    Conlon AS; Taylor JM; Elliott MR
    Biostatistics; 2014 Apr; 15(2):266-83. PubMed ID: 24285772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Links between causal effects and causal association for surrogacy evaluation in a gaussian setting.
    Conlon A; Taylor J; Li Y; Diaz-Ordaz K; Elliott M
    Stat Med; 2017 Nov; 36(27):4243-4265. PubMed ID: 28786131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bayesian approach to surrogacy assessment using principal stratification in clinical trials.
    Li Y; Taylor JM; Elliott MR
    Biometrics; 2010 Jun; 66(2):523-31. PubMed ID: 19673864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solutions for surrogacy validation with longitudinal outcomes for a gene therapy.
    Roberts EK; Elliott MR; Taylor JMG
    Biometrics; 2023 Sep; 79(3):1840-1852. PubMed ID: 35833874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accommodating missingness when assessing surrogacy via principal stratification.
    Elliott MR; Li Y; Taylor JM
    Clin Trials; 2013; 10(3):363-77. PubMed ID: 23553326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials.
    Li Y; Taylor JM; Elliott MR; Sargent DJ
    Biostatistics; 2011 Jul; 12(3):478-92. PubMed ID: 21252079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
    Renfro LA; Shi Q; Sargent DJ; Carlin BP
    Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A maximum entropy approach for the evaluation of surrogate endpoints based on causal inference.
    Alonso A; Van der Elst W; Molenberghs G
    Stat Med; 2018 Dec; 37(29):4525-4538. PubMed ID: 30141219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of copula to model within-study association in bivariate meta-analysis of binomial data at the aggregate level: A Bayesian approach and application to surrogate endpoint evaluation.
    Papanikos T; Thompson JR; Abrams KR; Bujkiewicz S
    Stat Med; 2022 Nov; 41(25):4961-4981. PubMed ID: 35932152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm.
    Roberts EK; Elliott MR; Taylor JMG
    Stat Med; 2021 Dec; 40(29):6605-6618. PubMed ID: 34528260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
    Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T
    BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
    Tanaka S; Matsuyama Y; Ohashi Y
    Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint.
    Zigler CM; Belin TR
    Biometrics; 2012 Sep; 68(3):922-32. PubMed ID: 22348277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogacy validation for time-to-event outcomes with illness-death frailty models.
    Roberts EK; Elliott MR; Taylor JMG
    Biom J; 2024 Jan; 66(1):e2200324. PubMed ID: 37776057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative methods to evaluate trial level surrogacy.
    Abrahantes JC; Shkedy Z; Molenberghs G
    Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the relationship between association and surrogacy when both the surrogate and true endpoint are binary outcomes.
    Meyvisch P; Alonso A; Van der Elst W; Molenberghs G
    Stat Med; 2020 Nov; 39(26):3867-3878. PubMed ID: 32875590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A joint frailty-copula model for meta-analytic validation of failure time surrogate endpoints in clinical trials.
    Sofeu CL; Emura T; Rondeau V
    Biom J; 2021 Feb; 63(2):423-446. PubMed ID: 33006170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Joint modeling of progression-free survival and overall survival by a Bayesian normal induced copula estimation model.
    Fu H; Wang Y; Liu J; Kulkarni PM; Melemed AS
    Stat Med; 2013 Jan; 32(2):240-54. PubMed ID: 22806764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.